Colgate 2025-26: 2030 Strategy, Cocoa+Tariff Headwinds
FY25 revenue $20.38B (+1%); Op income $4.35B (-1%); NI $2.13B (-26%); EPS $2.63 (-25%). Q4 organic sales grew across all 4 categories. Completed 2025 strategy with $5B in sales; transitioned to 2030 strategy. FY26 guide: wide range on category growth + FX low-single-digit benefit + cost flexibility.
Key takeaways
- First clean year on the new "2030 strategy" framework. Colgate completed its 2025 strategy with $5B in incremental sales delivered (since 2020 launch). Pivoting to 2030 with focus on (a) strong global brands with global reach, (b) accelerated investment in science-based innovation, (c) Hill's Pet Nutrition continued growth, (d) emerging market mix.
- Q4 organic +1.5%, FY +3% (per mgmt commentary). Volume mix slightly negative on Prime 100 acquisition wrap + private label exit. Emerging markets ahead of developed.
- Hill's Pet Nutrition the high-margin segment — continuing structural growth in premium pet food + therapeutic nutrition.
- EPS declined 25% to $2.63. Major commodity headwinds (cocoa not direct but freight, energy, packaging) + tariff impact + FX. Underlying operations stable.
- FY26 guide is unusually wide — "if categories worsen, low end; if stable, mid; if improve, higher end." Mgmt explicitly modeled multiple scenarios to give themselves flexibility.
Business
Colgate-Palmolive is a global consumer products company with leading positions in oral care + personal care + pet nutrition + home care. Four product categories:
- Oral Care (~50% of revenue): Colgate toothpaste + brushes + mouthwash + Tom's of Maine + Hello + Sanex (Europe). Dominant global market share in toothpaste.
- Personal Care (~20% of revenue): Speed Stick + Sanex deodorant + Irish Spring + Soft Soap + Protex + Palmolive bar/liquid soap.
- Home Care (~13% of revenue): Ajax + Murphy Oil Soap + Suavitel + Fabuloso + Colgate household cleaning.
- Hill's Pet Nutrition (~17% of revenue, high-margin growth): Science Diet + Prescription Diet + new growth platforms. Pet food premiumization story.
Geographic mix: North America ~25% / Latin America ~25% / Europe ~15% / Asia Pacific ~15% / Africa-Eurasia ~5% / Hill's ~17%. Emerging markets growing faster than developed; LatAm + Africa-Eurasia + Asia Pacific the structural growth markets.
FY25 financial performance
| Metric (FY) | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue ($B) | 19.46 | 20.10 | 20.38 |
| Gross profit ($B) | 11.25 | 12.11 | 12.25 |
| Gross margin | 57.8% | 60.2% | 60.1% |
| Op income ($B) | 4.13 | 4.38 | 4.35 |
| Op margin | 21.2% | 21.8% | 21.3% |
| EBITDA ($B) | 4.25 | 4.85 | 3.96 |
| Net income ($B) | 2.30 | 2.89 | 2.13 |
| Diluted EPS ($) | 2.77 | 3.51 | 2.63 |
| FCF ($B) | 3.04 | 3.55 | 3.63 |
| Capex ($M) | -705 | -561 | -564 |
| Total debt ($B) | 9.06 | 8.51 | 7.99 |
| Dividends ($B) | -1.75 | -1.79 | -1.82 |
| Buyback ($B) | -1.13 | -1.74 | -1.21 |
Key dynamics:
- Gross margin held at 60.1% — pricing + productivity offsetting input cost.
- Op margin slightly compressed to 21.3% (-50bp) on tariff + FX + restructuring.
- FCF $3.63B (+2%) — better than P&L on working capital release.
- Debt down to $7.99B (-$0.52B). Deleveraging continues.
Capital allocation
- Capex: $-564M FY25 (2.8% of revenue). Steady.
- Dividends: $-1.82B FY25 (+2% YoY). Dividend Aristocrat with 60+ years of consecutive raises.
- Buybacks: $-1.21B FY25, moderated from $-1.74B FY24.
- M&A: Prime 100 acquisition (Australian premium pet food) integrated; minor private-label exit.
- Debt: $7.99B (-$0.52B YoY). Continued paydown.
FY26 outlook (per Q4 2025 call, 2026-01-30)
| FY26 framework | Direction |
|---|---|
| Net sales / organic sales growth | Wide range (category-dependent) |
| FX impact | Low-single-digit benefit (focused on H1) |
| Category growth scenario | Worsen → low end; Stable → mid; Improve → high end |
| Q4 momentum | Improving across most divisions except NA |
| Emerging markets vs developed | EM ahead of DM |
The intentionally-wide FY26 guide reflects category uncertainty + Colgate giving itself flexibility on commodity + FX inputs. Mid-range implies organic +mid-single-digit + EPS recovery off FY25 $2.63 base toward FY24 $3.51 trajectory.
Key risks
- Category growth deceleration: Multiple categories (toothpaste, deodorant, household cleaning) are mature; volume growth tied to emerging market consumer + channel mix.
- Commodity input costs: Packaging materials (resin, paperboard), oils + fats, fragrance ingredients all material. Pass-through generally works but with lag.
- FX: Latin America + Asia EM currencies key. USD strengthening compresses reported revenue.
- Tariff regime: Cross-border manufacturing footprint exposed to trade policy changes.
- Private label competition: Modest in oral care but real in personal/home care. Trade-down risk in recession.
- Hill's Pet Nutrition cycle: Pet adoption + premium pet food spending tied to consumer discretionary + recession sensitivity.
Bottom line
CL FY25 is the strategy transition year — completed 2025 plan ($5B incremental sales), pivoted to 2030 plan, FY full year organic +3% / Q4 +1.5%, EPS $2.63 (compressed by commodity + FX + tariff). FCF $3.63B + capital return $3.0B + dividend hike continuing the consumer staples model. FY26 guide wide-range reflects category uncertainty. The structural read: dominant global oral care + Hill's premium pet + emerging market exposure remain quality-of-business advantages. Risks are commodity input + FX + private label competition; manageable through pricing discipline + Hill's mix.
Citations
- Colgate-Palmolive Co. FY25 Form 10-K (filed February 2026, SEC EDGAR).
- Colgate Q4 2025 earnings call, 2026-01-30 — completed 2025 strategy with $5B incremental sales, transitioned to 2030 strategy, Q4 organic +1.5% all 4 categories, FY26 guide range scenario-based on category growth, FX low-single-digit benefit H1.
- Internal financial_statements view (consolidated annual + cash flow + capital structure).